Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mitral Valve Surgery for Rheumatic Heart Disease in Indigenous Australians: A 27-Year Cohort Study of Repair Versus Replacement Outcomes.

Heart, lung & circulation·2025

Same author

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy.

Journal of visualized experiments : JoVE·2025

Same author

Affinity enrichment of placental extracellular vesicles from minimally processed maternal plasma with magnetic nanowires.

The Analyst·2025

Same author

Rapid and high-sensitivity screening of pregnancy complications by profiling circulating placental extracellular vesicles.

Science advances·2025

Same author

Profiling the extracellular vesicles of two human placenta-derived mesenchymal stromal cell populations.

Experimental cell research·2024

Same author

Immunoaffinity-enriched salivary small extracellular vesicles in periodontitis.

Extracellular vesicles and circulating nucleic acids·2024

Search research articles

Related Experiment Video

Updated: Mar 15, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.

Sharenya Chelvaretnam¹, Kol Thida Mom¹, Carlos Andres Palma Henriquez¹

¹INOVIQ Ltd., Melbourne, VIC 3168, Australia.

International Journal of Molecular Sciences

|March 14, 2026

Summary

This summary is machine-generated.

Chimeric antigen receptor (CAR) technology is advancing cancer immunotherapy. CAR-derived extracellular vesicles (EVs) offer a novel cell-free platform for targeted cancer treatment, potentially enhancing efficacy and reducing toxicity.

Keywords:

cancer chimeric antigen receptor extracellular vesicles immunotherapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Related Experiment Videos

Last Updated: Mar 15, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Cancer immunotherapy has seen significant progress, especially with chimeric antigen receptor (CAR) technology.
Fifth-generation CARs are engineered to target tumor antigens and have been applied to T cells, NK cells, and macrophages.
Clinical successes of CAR-T, CAR-NK, and CAR-macrophage therapies highlight their therapeutic potential.

Purpose of the Study:

To review the therapeutic potential and immunogenic properties of CAR-derived extracellular vesicles (EVs).
To explore the role of CAR-derived EVs in modulating immune responses against cancer.
To examine the application of CAR-derived EVs as targeted delivery vehicles for chemotherapy.

Main Methods:

Review of current literature on CAR technology and extracellular vesicles.
Analysis of the mechanisms by which CAR-derived EVs interact with the immune system.
Evaluation of preclinical and clinical data on CAR-EV applications.

Main Results:

CAR-derived EVs present a promising cell-free therapeutic platform.
These EVs can deliver anticancer mediators and modulate immune responses.
CAR-EVs show potential for targeted delivery of chemotherapeutic agents.

Conclusions:

CAR-derived EVs represent a novel and adaptable approach in cancer immunotherapy.
Their cell-free nature offers advantages in delivery and potential for reduced toxicity.
Further research into CAR-EVs could lead to enhanced anti-tumor efficacy and improved patient outcomes.